
Opinion|Videos|February 28, 2025
ASCO 2025: Updates From NIAGRA Trial
Panelists discuss how incorporating both neoadjuvant and adjuvant treatment approaches into clinical trial designs has shown promising improvements in event-free survival outcomes across multiple cancer types.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















